GSK is to acquire Aiolos Bio for a $1 billion upfront payment and up to $400 million in regulatory milestone payments. The acquisition includes Aiolos’ AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter Phase II clinical development for asthma, with potential for additional indications. AIO-001 was exclusively licensed to […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!